Rosuvastatin

Generic Name: Rosuvastatin

Brand Names: Crestor, Ezallor, Roszet

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₈FN_₃O_₆S

CAS Number: 287714-41-4

Unique Ingredient Identifier: 413KH5ZJ73

Background: Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the e...

Indication: The FDA monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), and Homozygous Familial Hypercholesterolemia.
...

Associated Conditions: Atherosclerosis, Atherosclerotic Cardiovascular Diseases, Cardiovascular Disease (CVD), Cardiovascular Events, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Hypertriglyceridemias, Major Adverse Cardiovascular Events, Mixed Dyslipidemias, Postoperative Thromboembolism, Primary Hypercholesterolemia, Primary Hyperlipidemia

Associated Therapies: Lipid-Lowering Therapy, Primary Prevention of Cardiovascular Diseases

Clinical Trials

Potential Drug Interaction Between ALXN2040 and Rosuvastatin

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Rosuvastatin
Drug: ALXN2040

First Posted Date: 2023-02-01

Last Posted Date: 2023-04-14

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 20

Registration Number: NCT05708573

Locations: 🇺🇸
Clinical Trial Site, Baltimore, Maryland, United States

A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ARV-471
Drug: Rosuvastatin

First Posted Date: 2022-12-15

Last Posted Date: 2024-07-26

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT05652660

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986322
Drug: Methotrexate
Drug: Rosuvastatin
Drug: Metformin
Dietary Supplement: Glucose
Drug: Leucovorin

First Posted Date: 2022-11-14

Last Posted Date: 2024-03-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 76

Registration Number: NCT05615012

Locations: 🇺🇸
Local Institution - 0001, Miami, Florida, United States

Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects

Phase 1

Completed

Conditions: COVID-19

Interventions: Drug: EDP-235
Drug: Midazolam
Drug: Rosuvastatin
Drug: Caffeine

First Posted Date: 2022-10-26

Last Posted Date: 2023-04-27

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 24

Registration Number: NCT05594615

Locations: 🇺🇸
ICON, plc., Salt Lake City, Utah, United States

Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)

Phase 2

Recruiting

Conditions: Clonal Cytopenia of Undetermined Significance
Myelodysplastic Syndromes

Interventions: Drug: Atorvastatin
Drug: Rosuvastatin

First Posted Date: 2022-08-01

Last Posted Date: 2024-02-21

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 16

Registration Number: NCT05483010

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Dabigatran and Rosuvastatin in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dabigatran etexilate
Drug: Rosuvastatin
Drug: Daridorexant

First Posted Date: 2022-07-29

Last Posted Date: 2022-11-08

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 24

Registration Number: NCT05480475

Locations: 🇨🇿
CEPHA s.r.o., Pilsen, Czechia

A Study of Imlunestrant (LY3484356) in Female Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Imlunestrant
Drug: Omeprazole
Drug: Repaglinide
Drug: Quinidine
Drug: Rosuvastatin
Drug: Dextromethorphan
Drug: Digoxin

First Posted Date: 2022-07-06

Last Posted Date: 2022-11-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 113

Registration Number: NCT05444556

Locations: 🇺🇸
Altasciences Clinical Los Angeles, Inc, Cypress, California, United States
🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States